about
Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.Co-infections with cytomegalovirus and human herpesvirus type 7 in adult Polish allogeneic haematopoietic stem cell transplant recipients.High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantStrategies of pain reduction during the bone marrow biopsyA multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease.Infections due to alphaherpesviruses in early post-transplant period after allogeneic haematopoietic stem cell transplantation: Results of a 5-year survey.Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care.Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center Study.Analysis of the shedding of three β-herpesviruses DNA in Polish patients subjected to allogeneic hematopoietic stem cell transplantation: Six-year follow up.Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations.Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.Incidence of adenoviral DNAemia in Polish adults undergoing allogeneic haematopoietic stem cell transplantation.Beneficial effect of the CXCL12-3'A variant for patients undergoing hematopoietic stem cell transplantation from unrelated donors.Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients.Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Recommendations of the Fertility Preservation Working Group in Oncological, Hematological and Other Patients Treated With Gonadotoxic Therapies "ONCOFERTILITY" (GROF) of the Polish Society of Oncological Gynecology.AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes.Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantationDiagnosis of Klinefelter syndrome in the donor after peripheral blood stem cell transplantationAllogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcriptThe influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplantHLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donorLack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantationRole of donor HLA class I mismatch, KIR-ligand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation
P50
Q33342334-21D7208A-6DAF-4A07-B08E-5F8BDB25A554Q37501878-15FD3F38-ECA9-440E-A450-C618EA2E9F06Q37555831-7F68AF0E-CD75-4A6D-B6D1-F6568DF63825Q38065970-E34C59AF-B9D5-42E2-99D7-529B5613A6F3Q38155128-9D15514B-33B5-4A1F-86A4-7349A9D0EBFEQ39052923-DB5B6551-F6F4-493F-A6E9-19D7FEE67D42Q39134406-16DF04FA-A14F-4DC7-8895-67F65E49B62BQ39980117-8A826736-B46C-431A-AAC4-1EAFB7BFB747Q40063341-DC2C1453-389C-498E-94D6-802C1C35FE02Q41070196-8F1699A4-1128-4AEC-AFCC-8BB1A7F86E14Q41092832-FC743332-D22E-4DF6-918A-4B459D87514FQ41532474-F806146F-95B1-4394-A82C-DF82248B27F4Q41673886-ACA8052C-968B-4BA4-94AE-C0C41E321910Q41732815-D64982E1-1FA0-4FAE-8BD3-E1FFF8015D61Q47913869-5C57E92F-A702-4EFD-8A6F-1A929D9B0087Q48112267-DADEC4B3-69D6-4CDD-85C1-8F3B6EE0D407Q48846219-B84A0D9B-67C8-4B33-9521-A7A7AA51F31FQ50864328-B06A3C5B-E086-4AF5-92F9-649678E38F56Q52718440-AF058BA5-667C-4961-AA2C-5FDF30CE9E80Q53587963-67B0D05D-2C2A-4D30-87F3-92FFF4F9C60CQ54671498-B170A39E-AE46-4965-92D8-D414BA0C2406Q61657680-63978C67-6F58-47D4-9085-95163410B0EBQ73562901-885D0285-AD33-4CA6-A0DC-06AE4E367385Q79836229-ED898E91-E6B7-4563-82DE-63188956A6F8Q81229731-41CBABFF-6845-4C88-95B4-234E6764F977Q88236777-A70232E9-D355-4383-A8AB-28A83B8A58DCQ90417101-99BCE756-EB93-4867-898E-8332B3B64D15Q91245472-BBF656AE-1934-4744-AB14-B0BC77BAFCDF
P50
description
researcher ORCID ID = 0000-0003-3624-785X
@en
name
K Halaburda
@ast
K Halaburda
@en
K Halaburda
@nl
type
label
K Halaburda
@ast
K Halaburda
@en
K Halaburda
@nl
prefLabel
K Halaburda
@ast
K Halaburda
@en
K Halaburda
@nl
P31
P496
0000-0003-3624-785X